ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003

ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was deri...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 21; no. 1; pp. 877 - 22
Main Authors Wu, Yu-Peng, Zheng, Wen-Cai, Huang, Qi, Huang, Xu-Yun, Lin, Fei, Ke, Zhi-Bin, You, Qi, Zheng, Qing-Shui, Wei, Yong, Xue, Xue-Yi, Xu, Ning
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 04.12.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003. The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth. ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer.
AbstractList Background ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. Methods RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003. Results The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth. Conclusion ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer. Keywords: CircRNAs, Prostate cancer, ACACA, ND630
ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003. The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth. ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer.
BackgroundND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003.MethodsRT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003.ResultsThe function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth.ConclusionND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer.
ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003.BACKGROUNDND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003.RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003.METHODSRT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003.The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth.RESULTSThe function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth.ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer.CONCLUSIONND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer.
Abstract Background ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. Methods RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003. Results The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth. Conclusion ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer.
ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of ND630 in prostate cancer remains unknown. KIF18B, as an oncogene, plays a vital role in prostate cancer progression. circKIF18B_003 was derived from oncogene KIF18B and was markedly overexpressed in prostate cancer tissues. We speculated that oncoprotein KIF18B-derived circRNA circKIF18B_003 might have roles in prostate cancer promotion. The aim of this study was to validate whether ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. RT-qPCR was used to analyze the expression of circKIF18B_003 in prostate cancer cell lines and prostate cancer samples. circKIF18B_003 expression was modulated in prostate cancer cells using circKIF18B_003 interference or overexpression plasmid. We examined the function and effects of circKIF18B_003 in prostate cancer cells using CCK-8, colony formation, wound healing, and Transwell invasion assays and xenograft models. Fluorescence in situ hybridization (FISH) was performed to evaluate the localization of circKIF18B_003. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assay were performed to explore the potential mechanism of circKIF18B_003. The function of ND630 was determined in this study. circKIF18B_003 was overexpressed in prostate cancer tissues, and overexpression of circKIF18B_003 was associated with poor survival outcome of prostate cancer patients. The proliferation, migration, and invasion of prostate cancer cells were enhanced after up-regulation of circKIF18B_003. circKIF18B_003 is mainly located in the cytoplasm of prostate cancer cells, and the RIP and RNA pull down assays confirmed that circKIF18B_003 could act as a sponge for miR-370-3p. Further study demonstrated that up-regulation of circKIF18B_003 increased the expression of ACACA by sponging miR-370-3p. The malignant ability of prostate cancer cells enhanced by overexpression of circKIF18B_003 was reversed by the down-regulation of ACACA. We found that overexpression of circKIF18B_003 was associated with lipid metabolism, and a combination of ND-630 and docetaxel markedly attenuated tumor growth. ND630 could control ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. ND630 and circKIF18B_003 may represent a novel target for prostate cancer.
ArticleNumber 877
Audience Academic
Author You, Qi
Zheng, Qing-Shui
Huang, Qi
Xue, Xue-Yi
Zheng, Wen-Cai
Huang, Xu-Yun
Wei, Yong
Xu, Ning
Lin, Fei
Wu, Yu-Peng
Ke, Zhi-Bin
Author_xml – sequence: 1
  givenname: Yu-Peng
  surname: Wu
  fullname: Wu, Yu-Peng
– sequence: 2
  givenname: Wen-Cai
  surname: Zheng
  fullname: Zheng, Wen-Cai
– sequence: 3
  givenname: Qi
  surname: Huang
  fullname: Huang, Qi
– sequence: 4
  givenname: Xu-Yun
  surname: Huang
  fullname: Huang, Xu-Yun
– sequence: 5
  givenname: Fei
  surname: Lin
  fullname: Lin, Fei
– sequence: 6
  givenname: Zhi-Bin
  surname: Ke
  fullname: Ke, Zhi-Bin
– sequence: 7
  givenname: Qi
  surname: You
  fullname: You, Qi
– sequence: 8
  givenname: Qing-Shui
  surname: Zheng
  fullname: Zheng, Qing-Shui
– sequence: 9
  givenname: Yong
  surname: Wei
  fullname: Wei, Yong
– sequence: 10
  givenname: Xue-Yi
  surname: Xue
  fullname: Xue, Xue-Yi
– sequence: 11
  givenname: Ning
  orcidid: 0000-0001-7909-7025
  surname: Xu
  fullname: Xu, Ning
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38049827$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1vEzEQhleoiLaBP8ABWeLCZYvt_bB9QmmgEFHBBc7W2OvdOtrYwd5Q-u-ZNKU0FUI--OuZdzzj97Q4CjG4onjJ6Bljsn2bGVetKCmvSlqLlpbXT4oTVgtVNlK0Rw_Wx8VpzitKed3U6llxXElaK8nFSRG-vG8rSmwMU4pjJvMFDgKhI6Pf-I4kt0lxSLBe-zAQHwhu8wSTIxaCdYmYG2SG7QjTDpiuHHG_Nsnl7GMgsSfWJ_t5ecHkuaa0el487WHM7sXdPCu-X3z4tvhUXn79uFzML0vbtPVUVlRxZoyVjWmUEIoyoZyiFQhwpq6khF6IXhoLsgdqnIAGqspw0ddG2kZUs2K51-0irPQm-TWkGx3B69uDmAYNafJ2dLpTChrLO0e7BvulZNUpZhpgFHODaVHr3V5rszVr11mHrYLxQPTwJvgrPcSfmtFW1Qq_Z1a8uVNI8cfW5UmvfbZuHCG4uM2aS8zKuBQS0deP0FXcpoC90hylWCXxkX-pAbACH_qIie1OVM-FQIJTqpA6-weFo3Nrjz_ueo_nBwGvHlZ6X-IfuyDA94BFF-Tk-nuEUb3zpN57UmPR-taT-hqD5KMg69FBfmc58OP_Qn8Di4PjuA
CitedBy_id crossref_primary_10_1016_j_intimp_2024_113908
Cites_doi 10.1038/s41585-020-00400-w
10.1056/NEJMra1701695
10.1186/s12935-020-01421-6
10.3322/caac.21442
10.1016/j.cmet.2017.09.018
10.1111/and.14406
10.1093/nar/27.1.29
10.1177/0300060521992215
10.3389/fonc.2020.553045
10.1073/pnas.1520686113
10.1016/j.canlet.2016.09.020
10.1080/15476286.2019.1600395
10.1186/s12943-020-01268-5
10.1056/NEJMoa2209454
10.1038/s41391-022-00521-w
10.1016/j.jprot.2017.11.017
10.1038/s41419-021-03877-4
10.1126/science.1238522
10.1038/s41374-022-00743-5
10.1158/0008-5472.CAN-19-3806
10.1083/jcb.201705209
10.3322/caac.21660
10.1007/978-1-4939-6380-5_7
10.1016/j.cell.2018.12.021
10.1016/S0140-6736(14)61947-4
10.1186/s12943-018-0827-8
10.1186/s12943-019-1072-5
10.1038/s41419-021-03582-2
10.1261/rna.043687.113
10.1093/nar/gkw027
10.1016/j.tice.2019.09.001
10.1038/s41388-021-01867-6
10.21873/anticanres.13036
10.1016/j.canlet.2019.12.014
10.1080/15476286.2015.1128065
10.2147/OTT.S157440
10.1186/s13046-021-02029-y
10.1093/nar/gkt1248
10.20892/j.issn.2095-3941.2019.0452
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12967-023-04760-w
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 22
ExternalDocumentID oai_doaj_org_article_d99a5c2de0d5479983d91b5a10b59ab6
PMC10694902
A775472009
38049827
10_1186_s12967_023_04760_w
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Startup Fund for scientific research, Fujian Medical University
  grantid: 2020QH2034
– fundername: "Eyas Plan" Youth Top-notch Talent Project of Fujian Province
  grantid: SCYJHBJRC-XN2021
– fundername: ;
  grantid: 2020QH2034
– fundername: ;
  grantid: SCYJHBJRC-XN2021
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c564t-30921bbc85b597790179e903a7aeb4388af77f8bca8fa0be7a5a33b27f4b8c573
IEDL.DBID M48
ISSN 1479-5876
IngestDate Wed Aug 27 01:25:06 EDT 2025
Thu Aug 21 18:36:01 EDT 2025
Fri Jul 11 00:15:43 EDT 2025
Sat Jul 26 00:09:53 EDT 2025
Tue Jun 17 22:25:07 EDT 2025
Tue Jun 10 21:14:07 EDT 2025
Thu Apr 03 06:57:47 EDT 2025
Thu Apr 24 22:52:52 EDT 2025
Tue Jul 01 02:59:42 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords CircRNAs
Prostate cancer
ACACA
ND630
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-30921bbc85b597790179e903a7aeb4388af77f8bca8fa0be7a5a33b27f4b8c573
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-7909-7025
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-023-04760-w
PMID 38049827
PQID 2902138547
PQPubID 43076
PageCount 22
ParticipantIDs doaj_primary_oai_doaj_org_article_d99a5c2de0d5479983d91b5a10b59ab6
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10694902
proquest_miscellaneous_2898312878
proquest_journals_2902138547
gale_infotracmisc_A775472009
gale_infotracacademiconefile_A775472009
pubmed_primary_38049827
crossref_primary_10_1186_s12967_023_04760_w
crossref_citationtrail_10_1186_s12967_023_04760_w
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-12-04
PublicationDateYYYYMMDD 2023-12-04
PublicationDate_xml – month: 12
  year: 2023
  text: 2023-12-04
  day: 04
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of translational medicine
PublicationTitleAlternate J Transl Med
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References AM Grimaldi (4760_CR1) 2022; 26
D Xue (4760_CR36) 2019; 18
C Wang (4760_CR12) 2021; 81
S Raimondo (4760_CR13) 2018; 173
M Liu (4760_CR24) 2019; 16
Z Jiang (4760_CR17) 2021; 40
O Sartor (4760_CR5) 2018; 378
Y Zhong (4760_CR34) 2018; 17
T McHugh (4760_CR15) 2018; 217
H Sung (4760_CR2) 2021; 71
H Xu (4760_CR11) 2020; 472
RL Siegel (4760_CR4) 2018; 68
C Ma (4760_CR35) 2020; 19
B Ye (4760_CR37) 2019; 19
S Jamalzadeh (4760_CR27) 2022; 102
X Ding (4760_CR29) 2022; 54
H Ogata (4760_CR26) 1999; 27
Z Ji (4760_CR33) 2019; 61
T Gao (4760_CR32) 2020; 17
P Glažar (4760_CR22) 2014; 20
H He (4760_CR10) 2021; 49
YP Wu (4760_CR16) 2021; 12
K Nishi (4760_CR40) 2018; 38
WW Du (4760_CR20) 2016; 44
H Guo (4760_CR38) 2020; 10
J Godtman (4760_CR28) 2022; 387
M Rios Garcia (4760_CR39) 2017; 26
JE Wilusz (4760_CR7) 2013; 340
JH Li (4760_CR23) 2014; 42
G Harriman (4760_CR14) 2016; 113
MC Haffner (4760_CR3) 2021; 18
G Attard (4760_CR6) 2016; 387
M Gagliardi (4760_CR19) 2016; 1480
J Luo (4760_CR21) 2017; 384
DB Dudekula (4760_CR25) 2016; 13
JN Vo (4760_CR9) 2019; 176
Y Gao (4760_CR30) 2020; 20
Y Wu (4760_CR31) 2018; 11
X Wang (4760_CR8) 2021; 40
C Liu (4760_CR18) 2021; 12
References_xml – volume: 18
  start-page: 79
  year: 2021
  ident: 4760_CR3
  publication-title: Nat Rev Urol
  doi: 10.1038/s41585-020-00400-w
– volume: 378
  start-page: 645
  year: 2018
  ident: 4760_CR5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1701695
– volume: 20
  start-page: 334
  year: 2020
  ident: 4760_CR30
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-020-01421-6
– volume: 19
  start-page: 3431
  year: 2019
  ident: 4760_CR37
  publication-title: Mol Med Rep
– volume: 68
  start-page: 7
  year: 2018
  ident: 4760_CR4
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21442
– volume: 26
  start-page: 842
  year: 2017
  ident: 4760_CR39
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2017.09.018
– volume: 54
  year: 2022
  ident: 4760_CR29
  publication-title: Andrologia
  doi: 10.1111/and.14406
– volume: 27
  start-page: 29
  year: 1999
  ident: 4760_CR26
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/27.1.29
– volume: 49
  start-page: 300060521992215
  year: 2021
  ident: 4760_CR10
  publication-title: J Int Med Res
  doi: 10.1177/0300060521992215
– volume: 10
  year: 2020
  ident: 4760_CR38
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.553045
– volume: 113
  start-page: E1796
  year: 2016
  ident: 4760_CR14
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1520686113
– volume: 384
  start-page: 39
  year: 2017
  ident: 4760_CR21
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2016.09.020
– volume: 16
  start-page: 899
  year: 2019
  ident: 4760_CR24
  publication-title: RNA Biol
  doi: 10.1080/15476286.2019.1600395
– volume: 19
  start-page: 157
  year: 2020
  ident: 4760_CR35
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01268-5
– volume: 387
  start-page: 2126
  issue: 23
  year: 2022
  ident: 4760_CR28
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2209454
– volume: 26
  start-page: 228
  year: 2022
  ident: 4760_CR1
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/s41391-022-00521-w
– volume: 173
  start-page: 1
  year: 2018
  ident: 4760_CR13
  publication-title: J Proteomics
  doi: 10.1016/j.jprot.2017.11.017
– volume: 12
  start-page: 631
  year: 2021
  ident: 4760_CR18
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-03877-4
– volume: 340
  start-page: 440
  year: 2013
  ident: 4760_CR7
  publication-title: Science
  doi: 10.1126/science.1238522
– volume: 102
  start-page: 761
  year: 2022
  ident: 4760_CR27
  publication-title: Lab Invest
  doi: 10.1038/s41374-022-00743-5
– volume: 81
  start-page: 3509
  year: 2021
  ident: 4760_CR12
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-3806
– volume: 217
  start-page: 2403
  year: 2018
  ident: 4760_CR15
  publication-title: J Cell Biol
  doi: 10.1083/jcb.201705209
– volume: 71
  start-page: 209
  year: 2021
  ident: 4760_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 1480
  start-page: 73
  year: 2016
  ident: 4760_CR19
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-4939-6380-5_7
– volume: 176
  start-page: 869
  year: 2019
  ident: 4760_CR9
  publication-title: Cell
  doi: 10.1016/j.cell.2018.12.021
– volume: 387
  start-page: 70
  year: 2016
  ident: 4760_CR6
  publication-title: Lancet
  doi: 10.1016/S0140-6736(14)61947-4
– volume: 17
  start-page: 79
  year: 2018
  ident: 4760_CR34
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0827-8
– volume: 18
  start-page: 151
  year: 2019
  ident: 4760_CR36
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1072-5
– volume: 12
  start-page: 302
  year: 2021
  ident: 4760_CR16
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-03582-2
– volume: 20
  start-page: 1666
  year: 2014
  ident: 4760_CR22
  publication-title: RNA
  doi: 10.1261/rna.043687.113
– volume: 44
  start-page: 2846
  year: 2016
  ident: 4760_CR20
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkw027
– volume: 61
  start-page: 44
  year: 2019
  ident: 4760_CR33
  publication-title: Tissue Cell
  doi: 10.1016/j.tice.2019.09.001
– volume: 40
  start-page: 4338
  year: 2021
  ident: 4760_CR8
  publication-title: Oncogene
  doi: 10.1038/s41388-021-01867-6
– volume: 38
  start-page: 6683
  year: 2018
  ident: 4760_CR40
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.13036
– volume: 472
  start-page: 151
  year: 2020
  ident: 4760_CR11
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2019.12.014
– volume: 13
  start-page: 34
  year: 2016
  ident: 4760_CR25
  publication-title: RNA Biol
  doi: 10.1080/15476286.2015.1128065
– volume: 11
  start-page: 1707
  year: 2018
  ident: 4760_CR31
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S157440
– volume: 40
  start-page: 227
  year: 2021
  ident: 4760_CR17
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-021-02029-y
– volume: 42
  start-page: D92
  year: 2014
  ident: 4760_CR23
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkt1248
– volume: 17
  start-page: 371
  year: 2020
  ident: 4760_CR32
  publication-title: Cancer Biol Med
  doi: 10.20892/j.issn.2095-3941.2019.0452
SSID ssj0024549
Score 2.393137
Snippet ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the function of...
Background ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the...
BackgroundND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism. However, the...
Abstract Background ND630 is believed to be a new therapy pharmacologic molecule in targeting the expression of ACACA and regulating the lipid metabolism....
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 877
SubjectTerms ACACA
Acetyl-CoA Carboxylase - genetics
Acetyl-CoA Carboxylase - metabolism
Antibodies
Antigens
Biomarkers
Cell division
Cell Line, Tumor
Cell Movement - genetics
Cell proliferation
Cell Proliferation - genetics
Cholecystokinin
CircRNAs
Circular RNA
Cytoplasm
Disease
Enzymes
Fatty acids
Fluorescence in situ hybridization
Gene Expression Regulation, Neoplastic
Humans
Immunoprecipitation
In Situ Hybridization, Fluorescence
Kinesins - genetics
Kinesins - metabolism
Lipid metabolism
Lipids
Localization
Male
Medical prognosis
Metabolism
MicroRNAs - genetics
MicroRNAs - metabolism
ND630
Oncogenes
Prostate cancer
Prostatic Neoplasms - genetics
Proteins
Ribonucleic acid
RNA
RNA, Circular - genetics
Tumor cell lines
Up-regulation
Wound healing
SummonAdditionalLinks – databaseName: DOAJ Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-G31lAiCD1KubZImfdw7XU7Fe_Lg3sLko1g4u8vuHqf_vTNtumwR9MXXZkKT-cjMtJPfMPa2DMGBCJBDKWMu6UMTaO_yEvA4NCJQ-22qtriozy_l5yt1ddDqi2rCRnjgkXEnoWlA-SrEIiipMTkQoSmdgrJwqgE3gG2jz5uSqQllD9Oe6YqMqU-26NXwQED_lBdS10V-O3NDA1r_n2fygVOaF0weeKDlA3Y_hY58MS75IbsT-0fs7tf0c_wx6y8-1KLgqfh8y5HLZwsOfeDX3boLnPArh2KsH-iueNfzNd34wFiTexL9hrtfSDO0picCjAx5_JnqZHu-arnvNv7Lp2VpTgnr8wm7XH78dnaep3YKuVe13OWiaKrSOW-UI9C5hmwxNoUADdFJYQy0WrfGeTAtFC5qUCCEq3QrnfFKi6fsqF_18TnjrQFkqwoRsyXZthEEuNBiruu1MC6ojJUTd61PWOPU8uLaDjmHqe0oEYsSsYNE7G3G3u_nrEekjb9Sn5LQ9pSEkj08QN2xSXfsv3QnY-9I5JZsGZfnIV1JwE0SKpZdEDygpv9HGTueUaIN-vnwpDQ2nQFbWzUYPwmDJBl7sx-mmVTX1sfVDdIYXBSGCNpk7NmoY_stCYPZm6lwtplp32zP85G--z4ghJd0nRlf_-J_cOklu1eR5VANjzxmR7vNTXyFkdjOvR6M7jfXai71
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k2gICMhcUBRk9iOnRPaFlYFRE9U2ps1fgQileyyu1Xbf89M1rtthNRrPFZsz8tjj79h7H0ZggMRIIdSxlzSQRNo7_IS0BwaEaj8NmVbnNTHp_LbTM3SgdsqpVVubeJgqMPc0xn5QdWgNxJGSf1p8TenqlF0u5pKaNxl9wi6jFK69Ow64JIY_Gwfypj6YIW-Dc0Ceqm8kLou8ouRMxow-_-3zDdc0zht8oYfmj5iD9MGkk82HH_M7sT-Cbv_I12RP2X9yedaFDyloK84rvXRhEMf-Fm36AInFMshJesPOi3e9XxB7z5wx8k9CcCSuyukGQrUEwHuD3m8TNmyPZ-33HdL__3rtDSHhPj5jJ1Ov_w8Os5TUYXcq1quc1E0VemcN8oR9FxDGhmbQoCG6KQwBlqtW-M8mBYKFzUoEMJVupXOeKXFc7bXz_v4kvHWAC6rChFjJtm2EQS40GLE67UwLqiMldvVtT4hjlPhizM7RB6mthuOWOSIHThiLzL2cddnscHbuJX6kJi2oySs7OHDfPnLJtWzoWlA-SrEIqD0YHgpQlM6BWWBKwCuztgHYrkljcbheUgPE3CShI1lJwQSqOkWKWP7I0rURD9u3gqNTZZgZa_lNmPvds3Uk7Lb-jg_RxqDg8KNgjYZe7GRsd2UhMEYzlTY24ykbzTncUvf_R5wwkt61Iy_f3X7uF6zBxXpBOXoyH22t16exze401q7t4M6_QPt5CZM
  priority: 102
  providerName: ProQuest
Title ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
URI https://www.ncbi.nlm.nih.gov/pubmed/38049827
https://www.proquest.com/docview/2902138547
https://www.proquest.com/docview/2898312878
https://pubmed.ncbi.nlm.nih.gov/PMC10694902
https://doaj.org/article/d99a5c2de0d5479983d91b5a10b59ab6
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELf2ISFeEN8ERmUkJB5QIInt2HlAqB2rBmgVmqg08WL5K1CppKXttO2_585NyyImJF76EJ_T-D58d8n5d4S8zL23hnmTmpyHlOOLJiOdTXMD26FiHttvY7XFqDwe809n4myHbNodtQxc3pjaYT-p8WL65vLX1Xsw-HfR4FX5dgk-C8wdvE-acVlm6cUu2QfPJNFQT7j6g70nYjicc1mlAraBzSGaG-_RcVQRz__vXfua2-qWVF7zUcO75E4bXNL-WhvukZ3Q3Ce3TtrP5w9IM_pQsoy25elLCnI47FPTeDqdzCeeIsJlLNf6CQ6NTho6xzMhEI1Sh8qxoPYKaGLzeiSA2JGGy7aStqGzmrrJwn3-OMzVANFAH5Lx8Ojr4XHaNlxInSj5KmVZVeTWOiUswtJVaK2hypiRJljOlDK1lLWyzqjaZDZIIwxjtpA1t8oJyR6RvWbWhCeE1soAW4UPkE_xug6GGetryIadZMp6kZB8w13tWjRybIox1TErUaVeS0SDRHSUiL5IyOvtnPkai-Of1AMU2pYScbTjhdniu27NUvuqMsIVPmRegFZUoJ1VboXJM-CAsWVCXqHINeofPJ4z7aEFWCTiZuk-AghK_MKUkIMOJVip6w5vlEZvlFwXFURYTAFJQl5sh3EmVr41YXYONAoeCoIIqRLyeK1j2yUxBfmdKmC26mhfZ83dkWbyI2KI53jgGf7-6X_x9Bm5XaCJYDkPPyB7q8V5eA5B2cr2yK48kz2yPzgafTntxVcbvWh98Hs6-PYbZNM0Qg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BqdBLwg7gQGGAnEA4qWxE7sPCDUbqtaulUIbdLejG8ZlUZa2k5lP8U3ck6adIuQ9rbX-Dixfe7xuRDyPnbOaOZ0qGPuQ44_mrSwJow1iEPJHLbfxmiLcTY44V9P09Mt8rfJhcGwykYmVoLaTS3-I99NctBGTKZcfJn9DrFrFN6uNi001mQx8pcrcNkWn4f7gN8PSdI_ON4bhHVXgdCmGV-GLMqT2BgrU4O113IkSZ9HTAvtDWdS6kKIQhqrZaEj44VONWMmEQU30qaCwXvvkG3OwJXpkO3ewfjb96vqfuBuNak5MttdgDYFQQR6MYy4yKJw1VJ_VZeA_3XBNWXYDtS8pvn6D8mD2mSl3TWNPSJbvnxM7h7Vl_JPSDnez1hE66D3BQXs7nWpLh09n8wmjmLdzCoI7BeoSTop6QwzTcDGpRZJbk7NJcCcVX3EAAAsUur_1PG5JZ0W1E7mdjTsx7KHNUafkpNbOfBnpFNOS_-C0EJqONbUefDSeFF4zbRxBfjYVjBpXBqQuDldZesa59hq41xVvo7M1BojCjCiKoyoVUA-bebM1hU-boTuIdI2kFidu3ownZ-pmtmVy3Od2sT5yAG9gkPLXB6bVMcRnIA2WUA-IsoVyhBYntV1KgRsEqtxqS6WJRR4bxWQnRYk8L5tDzdEo2rZs1BXnBKQd5thnInxdKWfXgCMhEWBaSJkQJ6vaWyzJSbBa5QJzJYt6mvtuT1STn5WlcljTKOGz7-8eV1vyb3B8dGhOhyOR6_I_QT5AyOE-A7pLOcX_jXYeUvzpmYuSn7cNj__A77VZNU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ND630+controls+ACACA+and+lipid+reprogramming+in+prostate+cancer+by+regulating+the+expression+of+circKIF18B_003&rft.jtitle=Journal+of+translational+medicine&rft.au=Wu%2C+Yu-Peng&rft.au=Zheng%2C+Wen-Cai&rft.au=Huang%2C+Qi&rft.au=Huang%2C+Xu-Yun&rft.date=2023-12-04&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-023-04760-w&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12967_023_04760_w
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon